Clarissa C. Forneris

Apr 1, 2023 | dx.doi.org | Nicole R. Hauser |Clarissa C. Forneris |Kendra A. Ireland |Vasiliki T. Chioti

The emergence of multidrug-resistant pathogens poses a threat to public health and requires new antimicrobial agents. As the archetypal glycopeptide antibiotic (GPA) used against drug-resistant Gram-positive pathogens, vancomycin provides a promising starting point. Peripheral alterations to the vancomycin scaffold have enabled the development of new GPAs. However, modifying the core remains challenging due to the size and complexity of this compound family.